Ticagrelor (AR-C 126532XX), produced by AstraZeneca, is an inhibitor of platelet aggregation. Unlike clopidogrel, ticagrelor is not a prodrug required metabolic activation. The drug was approved for use in the European Union by the European Commission on December 3, 2010, and by the US FDA on July 20, 2011. Its trade names are Brilinta (US), Brilique(EU) and Possia(EU).
Molecular Weight:
522.57
Purity:
>99.99%
CAS Number:
[274693-27-5]
Formula:
C23H28F2N6O4S
Target:
P2Y Receptor|||Cytochromes P450
* VAT and and shipping costs not included. Errors and price changes excepted